All In Biotech

Drug Trial Radar · NCT07754045

Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Evaluating the Efficacy and Safety of Oral LUM-201 as an Adjunct to Oral Semaglutide for Improving Physical Function in Older Adults With Obesity

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 202 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

202

Planned (sponsor's estimate)

Start

Feb 15, 2027

Primary completion

Feb 15, 2028

Study completion Feb 15, 2028

Sponsor

Lead sponsor
Lumos PharmaIndustry
Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\^2, between the ages of 60 and 85 years that have mild functional impairment.

Conditions

  • Obesity & Overweight

Interventions

  • LUM-201Drug

    Daily (AM) oral Tablet at 25 mg

  • PlaceboDrug

    Daily (AM) oral Tablet

  • SemagludtideDrug

    Daily (AM) oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26.Time frame: From Day 1 to week 26

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.